Breaking News

Drug Discovery CRO NovAliX Partners with Instrument Provider Bruker

Aim to jointly accelerate the incubation, deployment, and support of cutting-edge biophysical methods.

Author Image

By: Charlie Sternberg

Associate Editor

NovAliX, a Contract Research Organization (CRO) specializing in drug discovery, has announced a strategic alliance with Bruker, a leading provider of scientific instruments. The partnership involves Bruker taking a minority ownership stake in NovAliX.   The investment aims to leverage NovAliX’s expertise in structural biology, biophysics, and pharmacology to develop innovative analytical solutions that enhance drug discovery success. By combining Bruker’s advanced analytical capabilities with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters